Gennao Bio Announces Acceptance of Abstract for Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NEW HOPE, NJ – (COMMERCIAL THREAD) –Organic Gennao, a privately-held genetic drug company that develops world-leading targeted nucleic acid therapies, today announced that an abstract presenting the preclinical results of its proprietary non-gene monoclonal antibody nucleic acid delivery system (GMAB) has been selected for poster presentation at the 2021 International Conference on Molecular Targets and Cancer Therapeutics, organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC). The conference will be held virtually from October 7, 2021 to October 10, 2021.
Gennao’s GMAB technology platform uses a novel cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of several types of nucleic acids, including messenger ribonucleic assistance (RNA), RNA synthetic, RNA interference, deoxyribonucleic acid, antisense oligonucleotides and gene editing. molecules. Gennao Bio is developing this delivery system by initially focusing on oncology and monogenic skeletal muscle diseases.
The details of the presentation are as follows:
Title: Systemic targeting of medulloblastoma using monoclonal antibody penetrating cells and binding nucleic acids.
Poster Number: P135
Authors: Elias Quijano, Min Soo Kwang, Bruce C. Turner, Stephen Squinto, Ranjit Bindra, W. Mark Saltzman, and Peter M. Glazer.
The full summary and poster presentation can be viewed at the AACR-NCI-EORTC Annual Meeting website Effective October 7, 2021 at 9 a.m. ET.
About Gennao Bio
Gennao Bio is a privately held genetic drug company that develops world-class, targeted nucleic acid therapies using proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel cell-penetrating antibody to bind non-covalently and deliver therapeutic levels of a wide variety of nucleic acid payloads to selected cells. This non-viral delivery platform differs from traditional gene delivery systems in that it can deliver multiple types of nucleic acids, allows for repeated dosing, and uses well-established manufacturing processes. Gennao Bio is developing this delivery system by initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.